Read the actual label
Regulatory checkpoint · FDA label revised February 2026
Does the molecule’s name tell the whole approval story?
Subject One finds two folders bearing the same molecule’s name and different headings. He reaches for one giant approval stamp. Doctide replaces it with a reading lamp. “Start with the product and the indication.”
What changes here
Approval has boundaries, and animal findings must stay distinct from human findings. [1]
Read the study details & dates
Read the actual label
The retrieved FDA Saxenda label identifies subcutaneous liraglutide for long-term weight management with diet/activity measures in specified adults and eligible patients aged 12 or older. This is a label checkpoint, not a new trial: no comparator, phase or registry identifier applies. The preceding human episodes identify NCT01272219 and NCT01179048; they do not describe the same population or purpose. [1]
What this does not establish
The February 2026 label was retrieved November 10; its revision is not today’s news. This selected journey is not a complete preclinical dossier. Product-specific labeling does not validate other formulations or mixtures.
Original sources
Reviewed November 10, 2026. Official FDA label; rodent tumor evidence is separately identified. No dosing directions or recruitment claims.
Journal update record
2026-11-10 · Added six linked liraglutide episodes, separating weight-management studies, cardiovascular outcomes, secondary kidney findings and label evidence. Kept serious harms, deaths, uncertain causality and missing follow-up visible. No trial enrollment or individualized treatment claim.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story